**4/1/2022**

# CURRICULUM VITAE

**BIOGRAPHICAL**

**Name:** Ryan P. Smith, M.D.

**Home Address:** 231 Cornwall Drive **Birth Place:** Kittanning, PA

Pittsburgh, PA 15238

**Home Phone:** 412-445-9797 **Citizenship:** USA

**Business Address:** UPMC St. Margaret **E-Mail:** [smithrp@upmc.edu](mailto:smithrp@upmc.edu)

Dept. of Radiation Oncology

815 Freeport Road

Pittsburgh, PA 15215

**Business Phone:** 412-784-4900 **Business Fax:** 412-784-4905

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**EDUCATION and TRAINING**

**Undergraduate:**

1991-1995 Allegheny College B.S. Biology

Meadville, PA May 1995 Magna cum laude

**Graduate:**

1995-1999 Temple University M.D.

Philadelphia, PA May 1999

**Postgraduate:**

1999-2000 Albert Einstein Medical Center

Philadelphia, PA Internship

* 1. University of Pennsylvania Program Director

#### Philadelphia, PA Residency Eleanor Harris, MD

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**APPOINTMENTS and POSITIONS**

**Academic:**

2016-present University of Pittsburgh Clinical Professor

School of Medicine,

Department of Radiation Oncology,

Pittsburgh, PA

2009-2016 University of Pittsburgh Clinical Associate Professor

School of Medicine,

Department of Radiation Oncology,

Pittsburgh, PA

2008-present University of Pittsburgh Cancer Residency Program Director

Institute, Pittsburgh, PA

2007-present UPMC St. Margaret’s Hospital Medical Director

Pittsburgh, PA

2004-2009 University of Pittsburgh Clinical Assistant Professor

School of Medicine,

Department of Radiation Oncology,

Pittsburgh, PA

2003-2004 University of Pennsylvania Chief Resident

Philadelphia, PA

2002-2003 University of Pennsylvania Assistant Chief Resident

Philadelphia, PA

2001-2004 Editorial Assistant for Oncolink.com

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**CERTIFICATION and LICENSURE**

**Certification:**

##### American College of Radiation Oncology 2005

**Licensure:**

### Pennsylvania 2001

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

# PROFESSIONAL and SCIENTIFIC SOCIETY MEMBERSHIPS

##### American Society for Therapeutic Radiation Oncologists 2000

##### American Society of Clinical Oncologists 2000

American Brachytherapy Society 2007

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**HONORS and AWARDS**

Listed as one of the “Best Doctors in Pittsburgh” 2016-2024

Leo Criep Excellence in Patient Care Award 2011, 2018

University of Pittsburgh Cancer Institute (UPCI) 2005-2006

Teacher of the Year Award for Radiation Oncology

Association of Residents in Radiation Oncology (ARRO) 2005-2006

Teacher of the Year Award 2022-2023

Joseph C. Doane Memorial Prize 1999

Alpha Omega Alpha 1999

AMA (Student Chapter) Vice-President 1996-1997

Richard L. Brown Award 1995

Phi Beta Kappa 1994

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

###### PUBLICATIONS and PRESENTATIONS

**Referred Articles:**

1. Coates EL, Welles CM, **Smith RP**. Identification of carbonic anhydrase activity in bullfrog olfactory neurons: histochemical localization and role in CO2 chemoreception. J Comp Physio l182:163-174, 1998.
2. Hahn SM, **Smith RP**, Freidberg J. Photodynamic therapy for mesothelioma. Curr Treat Options Oncol 2:375-383, 2001.
3. **Smith RP**. Photodynamic therapy. Curr Probl Cancer 26:61-108, 2002.
4. **Smith RP**, Devine P, Jones H, DeNittis A, Whittington R, Metz JM. Internet use by patients with prostate cancer undergoing radiotherapy. Urology 62:273-277, 2003.
5. **Smith R**, Kao GD. Pictures, progress and perplexities: the immediate cell biological effects of ionizing radiation. Cancer Biol Ther 3:602-607, 2004.
6. **Smith R**, McKenna WG. The Basics of Radiation Therapy. In: Clinical Oncology, 3rd Edition, Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (eds.),pp. 537-578. Philadelphia: Elsevier, Inc., 2004.
7. **Smith RP**, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 164:1227-1230, 2004.
8. **Smith RP**, Hahn SM. Treatment of Mesothelioma with Radiotherapy. In Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Transitional Therapies. Pass HI, Vogelzang NJ, and Carbone M (eds.) Springer Science + Business Media, Inc., 2005
9. Sarkar A, Santiago RJ, **Smith R**, Kassaee A. Comparison of manual vs. automated multimodality (CT-MRI) image registration for brain tumors. Med Dosim 30:20-24. 2005
10. [**Smith RP**, Bloch P, Harris EE, McDonough J, Sarkar A, Kassaee A, Avery S, Solin LJ.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15890577&query_hl=4) Analysis of interfraction and intrafraction variation during tangential breast irradiation with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 62:373-378, 2005
11. **Smith RP**, Heron DE, Huq MS, Yue NJ. Modern radiation treatment planning and delivery-From Rontgen to real time. Hematol Oncol Clin N Am 20:45-62, 2006.
12. Heron DE, **Smith RP**, Andrade RS. Advances in image-guided radiation therapy-the role of PET-CT. Med Dosim 31:3-11, 2006.
13. Owonikoko T, Agha M, Balassanian R, **Smith R**, Raptis A. Gemtuzumab Therapy for Isolated Extramedullary Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplant. Nature Clinical Practice Oncology, Aug; 4(8):491-495, 2007.
14. **Smith RP**, Schuchert M, Komanduri K, Burton S, Heron DE, Luketich J, D’Amato T, Landreneau R. Dosimetric Evaluation of Radiation Exposure During I-125 Vicryl Mesh Implants: Implications for ACOSOG z4032[,](javascript:AL_get(this,%20'jour',%20'Ann%20Surg%20Oncol.');) 14(12):3610-3613, 2007.
15. Nayak J, Walvekar R, Andrade RS, Daamen N, Lai SY, Argiris A, **Smith RP**, Heron DE, Ferris RL, Johnson J, Branstetter B. Deferring Planned Neck Dissection Following Chemoradiaion for Stage IV Head and Neck Cancer: The Utility of PET-CT. The Laryngoscope 117(12):2129-2134, 2007.
16. **Smith RP**, Beriwal S, Komanduri K, Gibbons E, Benoit R: Planning based on postneedle Volume with Early Dosimetric Assessment Is Beneficial for Cesium-131 Permanent Prostate Seed Implantation. Brachytherapy. 7 (3):237-241, 2008.
17. Gibbons EP, **Smith RP**, Beriwal SB, Krishna K, Benoit RM: Overcoming Pubic Arch Interference with Free Hand Needle Placement in Men Undergoing Prostate Brachytherapy. Brachytherapy 8(1):74-78, 2008.
18. Jacobs BL, Gibbons EP, **Smith RP**, Beriwal S, Komanduri K, Benoit RM: Comparison Between Real-time Intra-operative Ultrasound-based Dosimetry and CT-based Dosimetry for Prostate Brachytherapy using Cesium-131. Technol Cancer Res Treat 7(6):463-70, 2008.
19. Heron DE, Andrade RS, Beriwal S, **Smith RP**: PET-CT in Radiation Oncology-The Impact on Diagnosis, Treatment Planning and Assessment of Treatment Response. Am J Clin Oncol. Volume 31 (4):352-362, 2008.
20. Williamson R, Smaldone MC, Gibbons EP, **Smith RP**, Beriwal S, Benoit RM: Prostate Brachytherapy After Ileal Pouch-Anal Anastomosis Reconstrucion. Urology 73:369-373, 2009.
21. Gibbons EP, Jacobs BL, **Smith RP**, Beriwal S, Krishna K, Beniot, RM: Dosimetric Outcomes in prostate brachytherapy: Is downsizing the prostate with androgen deprivation necessary? Brachytherapy 8(3):304-8, 2009.
22. Corcoran AT, **Smith RP**, Benoit RM. Case report of significant bleeding associated with prostate brachytherapy. Can J Urol 16(3):4682-3, 2009.
23. Kehwar TS, Jones HA, Huq MS, Beriwal S, Benoit RM, **Smith RP**: Effect of edema associated with 131Cs prostate permanent seed implants on dosimetric quality indices. Med Phys 36(8):3536-42, 2009.
24. Gokhale AS, McLaughlin BT, Flickinger JC, Beriwal S, Heron DE, Ferris RL, Johnson J, Gibson MK, Argiris A, **Smith RP**. Clinical and Dosimetric Factors Associated with a Prolonged Feeding Tube Requirement in Patients Treated with Chemoradiation (CRT) for Head and Neck Cancer. *Annal of Oncol* 21(1):145-151, 2009.
25. McLaughlin BT, Gokhale AS, Shuai Y, Diacopoulos J, Carrau R, Heron DE, **Smith RP**, Gibson MK, Ferris RL, Grandis JR, Johnson JT, Argiris A. [Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience.](http://www.ncbi.nlm.nih.gov/pubmed/19877245?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2) Laryngoscope 120(1):71-5, 2010.
26. Gokhale A, **Smith RP**, Benoit RM, Beriwal. Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with cesium-131 brachytherapy for prostate cancer. Brachytherapy 9(4):324-8, 2010.
27. Jacobs BL, **Smith RP**, Beriwal S, Benoit RM. Acute Bowel Morbidity after Prostate Brachytherapy with Cesium-131 Brachytherapy. Brachytherapy 10(1):51-6, 2011.
28. Jacobs BL, **Smith RP**, Beriwal S, Benoit RM. Acute Lower Urinary Tract Symptoms after Prostate Brachytherapy with Cesium-131. Urology 76(5):1143-7, 2010.
29. **Smith RP**, Jones HA, Kehwar TS, Benoit RM, Beriwal S. Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants. Int J Radiat Oncol Biol, Int J Radiat Oncol Biol Phys 81(3):745-50, 2011.
30. DeFoe SG, Beriwal S, Jones HA, Rakfal S, Heron DE, **Smith RP.** [Concurrent Chemotherapy and Intensity-modulated Radiation Therapy for Anal Carcinoma - Clinical Outcomes in a Large National Cancer Institute-designated Integrated Cancer Centre Network.](http://www.ncbi.nlm.nih.gov/pubmed/22075444) Clin Oncol (R Coll Radiol) 24(6):424-31, 2012.
31. Argiris A, Heron DE, **Smith RP**, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer. J Clin Oncol 28(36):5294-300, 2010.
32. O’Neill M, Heron DE, Flickinger JC, **Smith** RP, et al. Post-Treatment Quality of Life Assessment in Head and Neck Cancer Patients Treated with Intensity-Modulated Radiation Therapy (IMRT). Amer J Clin Oncol 34(5):478-82, 2011
33. Tomaszewski JJ, Smaldone MC, Makaroun S, **Smith RP**, Beriwal S, Benoit RM. Cesium 131 Versus Iodine 125 Implants for Prostate Cancer: Evaluation of Early PSA Response. Can J Urol, 17(5):5360-4, 2010.
34. Kehwar TS, Jones HA, Huq MS, **Smith RP**. [Influence of prostatic edema on 131Cs permanent prostate seed implants: a dosimetric and radiobiological study.](http://www.ncbi.nlm.nih.gov/pubmed/20932692) Int J Radiat Oncol Biol Phys 80(2):621-7, 2011.
35. Argiris A, Karamouzis MV, **Smith RP**, et al. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer, Ann Oncol, 22(11):2482-8, 2011.
36. Jacobs BL, **Smith** RP, Beriwal S, Benoit RM. [Changes in lower urinary tract symptoms after prostate brachytherapy.](http://www.ncbi.nlm.nih.gov/pubmed/23346119) J Contemp Brachytherapy, 3(3):115-120, 2011.
37. Beriwal S, **Smith** RP, Houser C, Benoit RM. [Prostate-specific antigen spikes with ¹³¹Cs brachytherapy. Is there a difference with other radioisotopes?](http://www.ncbi.nlm.nih.gov/pubmed/22818407) Brachytherapy 11(6):457-9, 2012.
38. Kehwar TS, Jones HA, Huq MS, **Smith** RP. [Edema-induced changes in tumor cell surviving fraction and tumor control probability in 131Cs permanent prostate brachytherapy implant patients.](http://www.ncbi.nlm.nih.gov/pubmed/23318378) J Appl Clin Med Phys. 14(1):3862, 2013.
39. Van Buren G 2nd, Ramanathan RK, Krasinskas AM, **Smith** RP, et. Al. [Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/23904005) Ann Surg Oncol. 20(12):3787-93, 2013.
40. Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, **Smith** R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A. [A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23849982) Lung Cancer 81(3):416-21, 2013.
41. Benoit RM, **Smith** RP, Beriwal S. [Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy.](http://www.ncbi.nlm.nih.gov/pubmed/25213299) Clin Oncol (R Coll Radiol). 2014 Dec;26(12):776-80.. Epub 2014 Sep 15. PMID: 25213299
42. Ling D, Vargo JA, **Smith RP**. Radiation-induced esophageal strictures in a patient with CREST syndrome. Practical Radiation Oncology*.*  2015:5-2.
43. Champ CE, Francis L, Clement, RJ, Dickerman R, **Smith RP**. Fortifying the Treatment of Prostate Cancer with Physical Activity. Prostate Cancer*.* 2016; 2016 PMID: 26977321.
44. Turner I I RM, Yabes JG, Woldemichael E, Deutsch MM, **Smith RP**, Werner RS, Jacobs BL, Nelson JB. [Prognostic implications of immediate PSA response to early salvage radiotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/27995853) Can J Urol. 2016 Dec;23(6):8568-8575. PMID:27995853
45. Glaser SM, Dohopolski MJ, Balasubramani GK, Benoit RM, **Smith RP**, Beriwal S. Brachytherapy boost for prostate Cancer: Trends in care and survival outcomes. Brachytherapy 2017 Mar-April;16(2): 330-341. PMID: 28159553
46. Glaser SM, Chen KS, Benoit RM, **Smith RP**, and Beriwal S. Long-Term Quality of Life in Prostate Cancer Patients Treated with Cesium 131. Int J Radiat Oncol Biol Phys 2017 Aug 1;98(5); 1053-1058, PMID: 28721888.
47. Champ CE, Ohri N, Klement RJ, Cantor M, Beriwal S, Glaser SM, **Smith RP**. [Assessing Changes in the Activity Levels of Breast Cancer Patients During Radiation Therapy.](https://www.ncbi.nlm.nih.gov/pubmed/28916400) Clin Breast Cancer. 2018 Feb;18(1):e1-e6.
48. Ling DC, Karukonda P, **Smith** RP, Heron DE, Beriwal S. [Declining brachytherapy utilization for high-risk prostate cancer-Can clinical pathways reverse the trend?](https://www.ncbi.nlm.nih.gov/pubmed/30217434) Brachytherapy. 2018 Sep 11. PMID 30217434
49. Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, **Smith RP**, Schultz C, Hartford AC, Zhang P, Mehta MP. [Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.](https://www.ncbi.nlm.nih.gov/pubmed/30496882) Int J Radiat Oncol Biol Phys. 2018 Nov 26. PMID 30496882
50. Ling DC, Chen KS, Benoit RM, Beriwal S, **Smith RP**. [Long-Term Patient-Reported Rectal Bleeding and Bowel-Related Quality of Life After Cs-131 Prostate Brachytherapy.](https://www.ncbi.nlm.nih.gov/pubmed/30853423) Int J Radiat Oncol Biol Phys. 2019 Mar 8. PMID 30853423
51. Champ CE**,** Beriwal S, **Smith RP**. Physician burnout and physician health – Three simple suggestions for a complex problem. Pract Radiat Onc. 2019 Sep -Oct;9(5):297-299. PMID 31077886
52. Benoit RM, Horne ZD, Houser CJ, **Smith RP**, Beriwal S. [Cesium-131 prostate brachytherapy: A single institutional long-term experience.](https://pubmed.ncbi.nlm.nih.gov/32249178/) Brachytherapy. 2020 May-Jun;19(3):298-304 PMID: 32249178
53. Patel AK, Houser C, Benoit R, **Smith RP,** Beriwal S. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR. Brachytherapy. 2020 Jul-Aug;19(4):477-483. PMID: 32331976
54. Schad M, Patel AK, Ling D, **Smith RP**, Beriwal S. Hypofractionated Prostate Radiation Therapy: Adoption and Dosimetric Adherence Through Clinical Pathways in an Integrated Oncology Network. JCO OP. 2020 Oct 23. PMID: 33095692
55. Rodríguez-Lopéz JL, Patel AK, Benoit R, Beriwal S, **Smith RP**. Treatment of Intermediate-risk Prostate Cancer with Cs-131: Long-term Results from a Single Institution. Brachytherapy, 2022 Jan-Feb; 21(1): 79-84. PMID: 34756821
56. Schad MD, Rodriquez-Lopez JL, Patel AK, Houser CJ, Horne ZD, Benoit RM, **Smith RP**, Beriwal S. Intraprostatic calcification and biochemical recurrence in men treated with cesium- 131 prostate brachytherapy. Brachytherapy 2021 July-Aug;20(4):859-865. PMID: 33994343
57. Keller A, Abdelhakiem M, Mulherkar R, Ghanta S, Benoit R, **Smith RP**, Beriwal S. Effect of Short-Term Corticosteroid Usage on Acute Urinary Toxicity Following Cs-131 Prostate Brachytherapy. Brachytherapy 2022 May. PMID 35514004
58. Abdelhakiem MK, Keller A, Bajpai RR, **Smith RP**, Beriwal S, Benoit R. Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life. Brachytherapy. 2023 Nov-Dec;22(6):808-821. PMID: 37648596.
59. Koerner SA, Benoit RM, Beriwal S, **Smith RP**. Redefining bladder neck dose in low-dose-rate prostate brachytherapy-Can we improve urinary toxicity without impacting disease control? Brachytherapy. 2024 Jan-Feb;23(1):58-63. PMID: 37821322.
60. Groszkiewicz A, Foust E, Palestra B, Ertel MC, Boisen M, Sukumvanich P, Smith SK, **Smith RP**, Vargo JA. Can an in-person hands-on applicator-based teaching session improve trainee knowledge and comfort with complex gynecologic brachytherapy? Brachytherapy. 2024 Mar 21:S1538-4721(24)00017-5. PMID: 38519351.
61. **Smith RP**, Mohammed MA, Beriwal S, Benoit RM. Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data. *In press*
62. **Smith RP, Comparison with SBRT, AJCO, In press**
63. **Smith RP, PSMA editorial, CGC, In press**

**Editorial, Editorial Comment, Letters**

1. Gupta AK, Meisner D, Neetu T, **Smith RP**, Swerdlow SH. Classical Nodular Sclerosis Hodgkin Lymphoma Presenting with Central Nervous System Disease [letter]. Southern Medical Journal 100(5):549-550, 2007.
2. Images in clinical medicine. Radiation recall and woody fibrosis. Champ CE, Smith RP. N Engl J. Med 2015 May 14; 372(20). PMID: 25970071
3. Meyer JE, Dilling TJ, Amdur RJ, Strasser JF, Tendulkar R, Lee WR, Jani AB, Elshaikh M, Poppe MM, Takita C, Currey A, Cheng SK, Jagsi R, Kuo JV, Chen AM, Dragun AE, Bradley K, **Beriwal** S, **Smith**RP, Chen RC, Rosenzweig K, Kim S, Mehta K. [In regard to Wu and Vapiwala et al.](https://www.ncbi.nlm.nih.gov/pubmed/26972659) Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):858-9. PMID:26972659
4. [In Regard to Maroongroge et al.](https://pubmed.ncbi.nlm.nih.gov/35777399/) Smith RP, Vargo JA, DeFoe SG, Kroskie-Smith S.Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):695. PMID: 35777399

**Oral and poster presentations**

1. Smith RP, et al.  The Effect of Positive Biopsy Cores on the Prognosis of Patients with Intermediate Risk Prostate Cancer Treated withCs-131 Prostate Brachytherapy. *Proc ASTRO* 2020
2. Smith, Ryan P., et al.  Feasibility and Efficacy of Bladder Neck Urethral Sparing Technique in Prostate Brachytherapy.  *Proc American Brachytherapy Society* 2021

**Invited Lectures:**

1. UPMC St. Margaret Grand Rounds. Innovative Strategies for Complex Diseases: Using Technology to Improve Outcomes. May 10, 2012
2. UPMC St. Margaret Grand Rounds. Radiation Therapy. November 12, 2015
3. UPMC St. Margaret Grand Rounds. Who Are Those People In The Basement?  An Overview of Radiation Oncology. July 11, 2019

**Recent Funding:**

$127,000 from IsoRay for 3 years: Ronald Benoit, Sushil Beriwal, Ryan P. Smith to evaluate outcomes analysis of CS131 PSI.